High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis
查看参考文献26篇
|
文摘
|
Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern. The current study aimed to observe the incidence of thalidomide-induced peripheral neuropathy among ankylosing spondylitis patients for 1 year after treatment. In this study, 207 ankylosing spondylitis cases received thalidomide treatment, while 116 ankylosing spondylitis cases received other treatments. Results showed that the incidence of thalidomide-induced peripheral neuropathy in the thalidomide group was higher than that in the non-thalidomide group. There was no significant difference in the incidence of neuropathy between the < 6 months medication and ≥ 6 months medication groups. There were no differences in the mean age, gender, or daily dose between the two groups. The incidence of peripheral neuropathy among patients receiving 25, 50, 75, or 100 mg thalidomide per day was 4.6%, 8.5%, 17.1%, 21.7%, respectively. The incidence was significantly different between the groups receiving 25 mg and 100 mg thalidomide. In conclusion, thalidomide can induce peripheral neuropathy within 1 year after treatment of ankylosing spondylitis; however, age and gender have no obvious impact on the incidence of peripheral neuropathy. The incidence of peripheral neuropathy is associated with increasing daily doses of thalidomide. |
|
来源
|
Neural Regeneration Research
,2015,10(5):814-818 【核心库】
|
|
DOI
|
10.4103/1673-5374.156988
|
|
关键词
|
nerve regeneration
;
peripheral nerve injury
;
thalidomide
;
ankylosing spondylitis
;
adverse reactions
;
peripheral neuropathy
;
prospective study
;
treatment
;
dose
;
treatment time
;
age
;
sex
;
neural regeneration
|
|
地址
|
1.
Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Liaoning, Shenyang
2.
Department of Rheumatology and Immunology, the First Affiliated Hospital of China Medical University, Liaoning, Shenyang
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1673-5374 |
|
基金
|
supported by the Natural Science Foundation of Liaoning Province of China
|
|
文献收藏号
|
CSCD:5427560
|
参考文献 共
26
共2页
|
|
1.
Bastuji-Garin S. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients.
J Invest Dermatol,2002,119:987-1020
|
CSCD被引
2
次
|
|
|
|
|
2.
Brandt J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
Arthritis Rheum,2000,43:1346-1352
|
CSCD被引
13
次
|
|
|
|
|
3.
Briani C. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.
Autoimmunity,2005,38:549-555
|
CSCD被引
5
次
|
|
|
|
|
4.
Clegg D O. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a department of veterans affairs cooperative study.
Arthritis Rheum,1996,39:2004-2012
|
CSCD被引
7
次
|
|
|
|
|
5.
Coelho A. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus, a 65 series of Brazilian patients.
Lupus,2005,14:434-439
|
CSCD被引
4
次
|
|
|
|
|
6.
Deng X. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept.
Rheumatol Int,2013,33:1409-1413
|
CSCD被引
9
次
|
|
|
|
|
7.
Direskeneli H. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease.
Clin Rheumatol,2008,27:373-375
|
CSCD被引
5
次
|
|
|
|
|
8.
Dougados M. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a sixweek controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
Arthritis Rheum,2001,44:180-185
|
CSCD被引
4
次
|
|
|
|
|
9.
Fernyhough P. Activation of nuclear factor-kappa B via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons.
J Neurosci,2005,25:1682-1690
|
CSCD被引
6
次
|
|
|
|
|
10.
Frankel H C. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity.
Int J Dermatol,2013,52:1407-1409
|
CSCD被引
1
次
|
|
|
|
|
11.
Garcia-Carrasco M. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis.
Joint Bone Spine,2007,74:500-503
|
CSCD被引
7
次
|
|
|
|
|
12.
Hall V C. Dermatlolgic side effects of thalidomide in patients with multiple myeloma.
J Am Acad Dermatol,2003,48:548-552
|
CSCD被引
5
次
|
|
|
|
|
13.
Haslett P A. Thalidomide eostimulates primary human T lymphocytes, preferentially inducing proliferation, eytokine production, and eytotoxie responses in the CD8+ subset.
J Exp Med,1998,187:1885-1892
|
CSCD被引
15
次
|
|
|
|
|
14.
Huang F. One-year open-label trial of thalidomide in ankylosing spondylitis.
Arthritis Rheum,2002,47:249-254
|
CSCD被引
15
次
|
|
|
|
|
15.
Liu Y. The antiangiogenic effect of thalidomide on occult liver metastases: an in vivo study in mice.
J Gastroenterol Hepatol,2009,24:1077-1081
|
CSCD被引
2
次
|
|
|
|
|
16.
Majumdar S. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by eeramide, lipopolyaaceharides, or phorbol ester.
J Immunol,2002,168:2644-2651
|
CSCD被引
6
次
|
|
|
|
|
17.
Mark T M. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Leuk Lymphoma,2014,55:2842-2849
|
CSCD被引
1
次
|
|
|
|
|
18.
Morawska M. Therapy-related peripheral neuropathy in multiple myeloma patients.
Hematol Oncol,2014
|
CSCD被引
7
次
|
|
|
|
|
19.
Matthews S J. Thalidominde: review of approved and investigational uses.
Clin Ther,2003,25:342-395
|
CSCD被引
8
次
|
|
|
|
|
20.
Ochonisky S. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients.
Arch Dermatol,1994,130:66-69
|
CSCD被引
2
次
|
|
|
|
|
了解气象卫星更多信息，请访问